Business
Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference
Calgary, Alberta--(Newsfile Corp. - July 10, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and ...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Highlights Key Asset at the 2023 Alzheimer's Association International ConferenceCalgary, Alberta--(Newsfile Corp. - July 10, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), is pleased to announce that it has been selected to present the Company's scientific advancement of its key asset MB-204 titled MB-204: A Novel Adenosine A2a Antagonist for AD, ADHD and Depression at the Alzheimer's Association International Conference (AAIC) Sunday, July 16, 2023: 7:00 AM – 11:55 PM CEST being held in Amsterdam.\"The adenosine A2a receptor (A2aR) is a very promising target for several neurological diseases, especially after the approval of Istradefylline, the first clinically approved A2aR antagonist for the treatment of Parkinson's disease,\" said Dr. Mark Williams, Chief Science Officer for Marvel. \"Since the success of Istradefylline, the A2aR has become a promising target for treating other conditions such as Alzheimer's Disease, depression and attention deficit disorders amongst others.\"\"As we complete the IND-enabling toxicology studies of our proprietary A2aR antagonist, MB-204, we continue to build awareness of MB-204 within both the academic and investment communities as, in our view, it has game-changing potential,\" said Rod Matheson, Chief Executive Officer of Marvel. \"Prominent conferences such as the Alzheimer's Association International Conference enables us to create opportunities to meet potential partners and continue to increase exposure to the potential of MB-204 within the scientific community as we prepare to begin clinical trials in the latter half of 2023.\"MB-204 is a fluorinated derivative of the U.S. FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration.About Marvel Biosciences Corp.Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a \"drug redevelopment\" approach to drug develop...